Medical Biotechnology Industry

Petri dish on colour scale; Source:

The industry covers an enormous range of products and services. The German medical biotechnology industry has made numerous innovations that have set global standards. The German biotech industry is a major driving force in Europe, both in terms of corporate representation and capacity to generate new - and profitable - intellectual property.

In 2015, the German biotechnology sector comprised 593 dedicated biotechnology companies, which employed 39,000 people. About 50-percent of the biotechnology companies based in Germany develop new drugs or diagnostic methods in the areas of human and animal medicine. Medical use ranks among the most important applications of biotechnology.

The German medical biotechnology sector is dominated by the production of biopharmaceuticals (e.g. antibodies), the manufacture of which is among the most demanding within the area of genetic technology. In addition to their use for making therapeutic drugs, DNA/RNA technologies also play a key role in genetic therapies and regenerative medicine as well as in medical biotechnology itself.

German medical biotechnology companies' sales in 2015 grew to EUR 3.3 billion compared to the previous year. As a productions site for biopharmaceuticals, Germany ranks first in Europe and second worldwide - German medical biotech products and technology platforms are sought after abroad and international demand is rising.

In 2014, 97 biologically active compounds were in Phase I-III clinical developments.

Sales of biopharmaceuticals on the German pharmaceuticals market grew by 10 percent to EUR 8.2 billion.

Market development

The importance of the biotechnology industry is rising. Compared to recent years more companies produce biotechnological products in Germany and more employees are working in this industry. Sales figures are stable and continue to remain high. In addition, Germany has a large and active research community that enjoys a high level of international respect.

Our standard of living in the future will be based on the foundation of a knowledge-based bio-economy. One cornerstone of this foundation is biotechnology.

German products are popular worldwide due to constantly increasing quality in development and production. This is reflected in the German market for biopharmaceuticals, with its sales of EUR 8.2 billion in 2015, amounting to an increase of 10 percent compared to the preceding year.


In-Vitro Diagnostics: In-vitro diagnosis (IVD) consists of instruments and apparatus (including software) that are used together with reagents in the laboratory or for on-site examination of samples that originated from the human body. They provide information about physiological or pathological conditions, congenital defects, recipient tolerance levels, and therapeutic condition monitoring. In this context, important innovative subareas include lab-on-chip technology, molecular diagnostics, immunodiagnostics, decentralized diagnostics, and individualized medicine.


Among the tasks of the Export Initiative of the German Healthcare Industry, HEALTH MADE IN GERMANY, is to inform and guide foreign individuals and companies who are interested in doing business in and with German healthcare. The Initiative informs you about German industry, holds events in your country and is available to answer your questions. Other functions are to promote lasting foreign market access and international network development for German small and medium-sized industries (SMEs).

In order to ensure that it is meeting their needs, HEALTH MADE IN GERMANY works in close cooperation with four working groups whose members are organizations representing specific sectors within the German healthcare industry. They are also available to address any queries you might have.

The members of the Medical Biotechnology Working Group are:

Association of German Biotech Companies (VBU)

German Association of Biotechnology Industries (DIB)

Biotechnologie-Industrieorganisation Deutschland (BIO Deutschland)